Dual Agonist Research Peptides
3 peptides with demonstrated dual agonist effects in research. Sorted by evidence quality from strongest to exploratory.
Overview
3 research peptides demonstrate dual agonist properties. This collection covers their mechanisms, evidence base, and research applications.
Mazdutide
Phase I–II Clinical Trials | Metabolic / Dual GLP-1/Glucagon Agonist
Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly (MW ~4233.7 g/mol).
Mechanism: Mazdutide is a fatty acid-acylated peptide that activates both the GLP-1 receptor and the glucagon receptor.
Pemvidutide
Phase I–II Clinical Trials | Metabolic / Dual GLP-1/Glucagon Agonist
Pemvidutide (ALT-801) is a dual GLP-1/glucagon receptor agonist being developed by Altimmune for the treatment of obesity and nonalcoholic steatohepatitis (NASH/MASH).
Mechanism: Pemvidutide is a dual-agonist peptide that activates both the GLP-1 receptor and the glucagon receptor.
Cotadutide
Phase I–II Clinical Trials | Metabolic / Dual GLP-1/Glucagon Agonist
Cotadutide (MEDI0382) is a dual GLP-1/glucagon receptor agonist developed by AstraZeneca (originally MedImmune). It is a once-daily injectable peptide designed to combine GLP-1 receptor-mediated glucose lowering and appetite suppression with...
Mechanism: Cotadutide is a synthetic peptide that activates both the GLP-1 receptor and the glucagon receptor in a balanced ratio.
Shop Research Peptides
Retatrutide 20mg
20mg
BPC-157 5mg
5mg
Ipamorelin 10mg
10mg
Semaglutide 10mg
10mg
TB-500 5mg
5mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Sermorelin 5mg
5mg
Tesamorelin 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe